Mechanisms of resistance to the TKI asciminib in CML

Massimo Breccia, MD, Sapienza University, Rome, Italy, discusses the mechanisms of resistance to the tyrosine kinase inhibitor (TKI) asciminib, used to treat chronic myeloid leukemia (CML). He notes that mutations to the myristoyl site and other genetic mutations potentially underlie resistance. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.